[HTML][HTML] Contemporary management of primary immune thrombocytopenia in adults
S Lakshmanan, A Cuker - Journal of Thrombosis and Haemostasis, 2012 - Elsevier
Immune thrombocytopenia (ITP) comprises a syndrome of diverse disorders that have in
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …
Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis
P Wojciechowski, K Wilson, J Nazir, I Pustułka… - Advances in …, 2021 - Springer
Introduction A network meta-analysis (NMA) was performed to assess the efficacy and safety
of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with …
of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with …
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal
J Burch, S Griffin, C McKenna, S Walker, J Paton… - …, 2012 - Springer
Following a licence extension to include those aged 6–11 years, the National Institute for
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal
B Kearns, M Lloyd Jones, M Stevenson… - Pharmacoeconomics, 2013 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of bevacizumab (Roche Products) to submit evidence for the clinical and cost …
manufacturer of bevacizumab (Roche Products) to submit evidence for the clinical and cost …
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical …
manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical …
Eltrombopag for treatment of thrombocytopenia-associated disorders
P Merli, L Strocchio, L Vinti, G Palumbo… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Eltrombopag is an orally bioavailable, non-peptide thrombopoietin receptor
agonist capable of stimulating platelet production through the differentiation of CD34+ …
agonist capable of stimulating platelet production through the differentiation of CD34+ …
Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal
R Wade, M Rose, AR Neilson, L Stirk… - …, 2013 - Springer
Abstract The National Institute for Health and Care Excellence (NICE) invited the
manufacturer of ruxolitinib (Novartis) to submit clinical and cost-effectiveness evidence for …
manufacturer of ruxolitinib (Novartis) to submit clinical and cost-effectiveness evidence for …
Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost …
manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost …